Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Uniphar PLC ( (GB:UPR) ) is now available.
Uniphar reported strong 2025 preliminary results, with revenue up 11.0% to €3.07bn and gross profit up 7.0% to €457.7m, driven by organic gross profit growth of 8.9%, the fastest since its IPO. Organic growth was broad-based, led by Uniphar Pharma with 15.5% growth and Medtech with 10.5%, while Supply Chain & Retail delivered 4.2% growth and expanded its pharmacy network to 482 outlets.
EBITDA rose 6.0% to €130.9m and adjusted EPS jumped 21% to 24.8 cent, supported by lower finance costs and a €35m share buyback that repurchased 13.4m shares. The group maintained a solid balance sheet with net bank debt of €171.1m and leverage at 1.6x, extended its credit facilities, achieved 99.1% free cash flow conversion, and reaffirmed its trajectory toward a €200m EBITDA target by 2028, underpinned by strategic investments such as a new high-tech Irish distribution hub and enhanced digital capabilities including the TouchStore acquisition.
Uniphar also highlighted its sustainability progress, reporting a 29.9% reduction in Scope 1 and 2 emissions since 2019 and maintaining strong ESG ratings including MSCI ‘AAA’ and a low-risk Sustainalytics industry score. For shareholders, the board proposed a total dividend of €5.2m, reflecting a 5.2% per-share increase, as management pointed to strong trading momentum entering 2026 and continued confidence in delivering predominantly organic growth in line with medium-term guidance.
More about Uniphar PLC
Uniphar plc is an international diversified healthcare services group headquartered in Dublin, serving more than 200 multinational pharmaceutical and medical technology manufacturers through its Pharma, Medtech, and Supply Chain & Retail divisions. Operating across Europe, North America, APAC and MENA and delivering to over 160 countries, the company focuses on improving patient access to pharmaco‑medical products by connecting manufacturers with healthcare stakeholders and leveraging its scale, growth and profitability.
See more data about UPR stock on TipRanks’ Stock Analysis page.